Volume | 3,561,170 |
|
|||||
News | - | ||||||
Day High | 1.78 | Low High |
|||||
Day Low | 1.59 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.71 | 1.59 | 1.78 | 1.61 | 1.71 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,323 | 3,561,170 | $ 1.67 | $ 5,930,368 | - | 0.92 - 3.789 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:04 | 50 | $ 1.66 | USD |
Lexicon Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
396.78M | 244.92M | - | 1.2M | -177.12M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lexicon Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.83 | 1.8575 | 1.59 | 1.66 | 4,185,452 | -0.20 | -10.93% |
1 Month | 2.10 | 2.47 | 1.59 | 1.96 | 3,278,105 | -0.47 | -22.38% |
3 Months | 1.89 | 3.73 | 1.59 | 2.46 | 4,746,742 | -0.26 | -13.76% |
6 Months | 1.09 | 3.73 | 0.92 | 2.03 | 3,610,931 | 0.54 | 49.54% |
1 Year | 2.53 | 3.789 | 0.92 | 2.06 | 2,966,632 | -0.90 | -35.57% |
3 Years | 5.15 | 6.3299 | 0.92 | 2.48 | 1,504,487 | -3.52 | -68.35% |
5 Years | 5.67 | 9.65 | 0.92 | 3.24 | 1,909,590 | -4.04 | -71.25% |
Lexicon Pharmaceuticals Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |